The opinion of the court was delivered by: BRUCHHAUSEN
The plaintiff moves for summary judgment.
This action was instituted, pursuant to 21 U.S.C. § 321 et sequa, to enjoin the defendant corporation and its president, Eugene J. Yoss, and those in participation with them from introducing into interstate commerce a certain drug containing phenylpropanolamine hydrochloride. The plaintiff, in its complaint, alleges that the labeling, accompanying the drug, represents and suggests that it is adequate and effective in weight reduction and control by curbing the appetite, as an adjunct in the control of obesity and that such statements are false and misleading.
The statutes, 21 U.S.C. §§ 321, 331, 332(a) and 502 empower the appropriate district court to grant an injunction against false or misleading labeling of drugs. Such labeling is termed misbranding.
Approximately twelve in rem actions were instituted by the Government in various district courts for the seizure and forfeiture of large quantities of the drug located within those jurisdictions. Pursuant to the libels, the drugs were seized by and now are in the possession of the Marshals. All of the cases were transferred to the District Court of New Jersey for disposition. The case of United States v. 60 28-Capsule Bottles, etc., Unitrol, D.C., 211 F.Supp. 207 was chosen as being representative of the others and tried before Judge Thomas F. Meaney. The defendant, Nysco Laboratories, Inc., appeared as the claimant therein. Judge Meaney wrote a lengthy opinion, containing findings, followed by judgment dated January 22, 1963. Included therein are the following provisions:
'An examination of all the evidence presented compels the conclusion that a daily dosage level of 75 mg. PPA has no significant pharma-cological value as a weight-reducing agent and that therefore any representation to the effect that PPA in that dosage is an adequate and effective appetite depressant or that it is adequate and effective in the management or control of obesity, would be a misbranding within the meaning of Title 21 U.S.C. § 352(a). The court finds that the labeling of claimant's product Unitrol represents that its sole active ingredient PPA is adequate and effective for the above purposes and consequently that this product is to be condemned according to the provisions of Title 21 U.S.C. § 334(d).
'Since the court has considered the biological and physiological effects of PPA, and the general character of the labeling which represents that PPA depresses the appetite with a consequent significant loss of weight, not confining its opinion to the greater claims made by the labeling in the instant case such as a loss of fourteen pounds in fourteen days, it feels that its conclusions are dispositive of all of the cases involving this product which are presently before the court.
'This opinion shall serve as findings of fact and conclusions of law.
'ORDERED, ADJUDGED, AND DECREED that the articles seized in each of these actions are misbranded as alleged in their respective Libels of Information, within the meaning of 21 U.S.C. 352(a), and pursuant to 21 U.S.C. 334(a), are condemned and forfeited to the United States of America, * * *
'ORDERED, ADJUDGED, AND DECREED that pursuant to 21 U.S.C. 334(d) and (f)(2), the United States Marshal in and for the respective Districts in which each of the articles have been seized shall destroy the seized articles and make return to this Court, but this provision shall be stayed * * * pending the final disposition of Claimant's appeal to the United States Court of Appeals for the Third Circuit.'
Undoubtedly the granting of the stay against destruction of the drug was to preserve the claimant's right of appeal, otherwise it would have been rendered moot. See United States v. 3 Unlabeled, etc., Dried Mushrooms, 7 Cir., 157 F.2d 722.
The said judgment has the effect of an injunction, restraining the claimant from distributing and marketing the seized drugs. As previously mentioned, those drugs remain in the possession of the Marshals.
The plaintiff contends that the said determination in the New Jersey court is res adjudicata of the issues in the subject action.
The claimant in the New Jersey action is Nysco Laboratories Inc., hereinafter called the Corporation. The defendants in the subject action are the Corporation and its president, Eugene J. Yoss. They admit that he is the president and has a voice in the ...